Subcarinal ventilation-assisted Y-shaped stent insertion under local anesthesia for patients with complex tracheobronchial stenosis: initial clinical experience

Radioactive and normal stent insertion for the treatment of malignant airway stenosis: A meta-analysis

PURPOSE

To demonstrate the advantage of radioactive stent (RS) for treating malignant airway stenosis (MAS) in reducing the stent restenosis rate and increasing overall survival (OS).

MATERIALS AND METHODS

Relevant studies in Pubmed, Embase, and Cochrane Library databases were identified. The rate of stent restenosis was the primary endpoint, whereas secondary endpoints were rates of stent-related complications, OS, and complete relief of dyspnea. This meta-analysis was conducted using RevMan v5.3.

RESULTS

Five total studies including 131 and 119 patients that underwent RS and normal stent (NS) insertion, respectively, were identified and included in this meta-analysis. Four studies were randomized controlled trials and one study was retrospective study. Pooled rates of complete relief of dyspnea, chest pain, hemoptysis, and fistula formation were similar between these two groups (p = 0.72, 0.77, 0.92, and 0.62, respectively). Pooled Δstenosis grade was comparable between these two groups (p = 0.72). RS insertion was linked to a significant lower pooled stent restenosis rate, increased OS, and higher 3-month survival rate relative to NS insertion (p< 0.00001, 0.0001, and 0.03, respectively). Pooled 6-months survival rates was higher in RS group without significant difference (p = 0.06). Pooled stent restenosis rate was significant higher in RS group based on each subgroup analysis. No evidence of publication bias for these endpoints was detected via funnel plot.

CONCLUSIONS

This meta-analysis revealed that RS insertion was sufficient to reduce rates of stent restenosis and to prolong patient OS relative to NS insertion when used to treat MAS.

Placement of self-expanding metallic tracheobronchial Y stent with laryngeal mask airway using conscious sedation under fluoroscopic guidance

Background

Central airway obstruction and fistula are treated with a tracheobronchial Y stent. In the currently used self‐expandable metal Y stents, the delivery system is 8 mm in diameter and requires either a 9 mm tracheal tube or rigid bronchoscope to enable airway control during insertion. In this study we present a novel technique of laryngeal mask airway (LMA) assisted Y stent insertion, enabling airway control during deployment of the Y stent.

Methods

All procedures using LMA in assisting Y stent insertions between 2014–2020 were reviewed. Data collected included demographics, clinical diagnosis and disease characteristics, indication, procedural success rates, clinical outcome and survival.

Results

A total of 10 patients with a median age of 61.5 years (range 37–73) underwent LMA assisted Y stent insertion. Indications for stent insertion were malignant disease with central airway obstruction or fistula. In all cases airway patency was achieved leading to improvement of symptoms and performance status. No procedural complications were reported. The median survival was 4.5 weeks (range: 2–26).

Conclusions

LMA assisted Y stent insertion enables airway control during the procedure. In comparison to silicone Y stent insertion, the procedure is less cumbersome, shorter in duration and does not require the use of general anesthesia or rigid bronchoscopy.

Key points

Significant findings of the study

LMA assisted Y stent insertion enables airway control during the implantation of metallic self‐expanding Y stent. The procedure does not require the use of general anesthesia or rigid bronchoscopy.

What this study adds

In this study we present the technique and outcomes of LMA assisted Y stent insertion. This method of Y stent insertion provides an additional treatment option for patients with central airway obstruction and fistula.

Self-expanding metallic Y-stent compared to silicone Y-stent for malignant lesions of the main carina: A single center retrospective study

BACKGROUND

Bifurcation stents are often required in patients with malignant airway obstruction or fistulization involving the main carina. The silicone Y stent is the most used but remains challenging to place. The self-expanding metallic Y (SEM) stent appears easy to use. The objective is to report the feasibility, efficacy, and tolerance of SEM Y stent compared to silicone Y stent in patients with malignant tumors involving the main carina.

PATIENTS AND METHODS

This retrospective single center study was performed between May 2004 and May 2017. All patients with malignant carina involvement treated with a bronchial Y stent were included.

RESULTS

Forty silicone Y stents and 38 SEM Y stents were placed. Seven stenting placements failed in the silicone Y group but none in the SEM Y stent group (P=0.008). The median duration of the procedure was 80min (25-210) in the silicone Y group and.50min (25-110min) in the SEM Y group (P=0.001). There was no significant difference in terms of early or late complications between the 2 groups. Nine silicone Y stents (26.5%) and 7 SEM Y stents (18.4%) were removed (P=0.4). The median survival time following stent insertion was 171 days (Interquartile range (IQR): 53-379) in the silicone Y group and 104 days (IQR: 53-230) in the SEM Y group.

CONCLUSION

If silicone Y stent remains the best solution for benign obstruction, SEM Y stent seems to be an easy alternative with no difference in terms of complication or ablation for malignant lesions involving the main carina.

Application of Micro-Tech stents in malignant carinal stenosis

Malignant carinal stenosis is a disease process that is not always suitable for treatment with a Y-shaped stent. When one of the main bronchi is completely obstructed and cannot be recanalized, or its distal lung tissue has lost function, inserting a Y-shaped stent is infeasible. In this complex condition, a cone-shaped stent is selected to maintain the patency of the trachea and the other main bronchus. The efficacy of the bare cone-shaped Micro-Tech stent to treat malignant carinal stenosis was evaluated in the current study. The medical records of 47 patients with malignant carinal stenosis who underwent Micro-Tech stent placement between January 2004 and October 2017 in Beijing Tian Tan Hospital (Beijing, China) were analyzed retrospectively. A total of 47 bare Micro-Tech stents (28 Y-shaped and 19 cone-shaped) were successfully inserted in the patients. Following stent placement, immediate satisfactory results were achieved in all patients, especially an improvement of dyspnea (100%), cough (81.1%) and stridor (100%). The Karnofsky scores were significantly increased (P<0.001), and the American Thoracic Society Dyspnea Index values were significantly decreased (P<0.001). Following a median of 88 days, initial bronchoscopic interventions were performed for tumor overgrowth (84.6%), stent fracture (7.7%) and granulation tissue (7.7%). Restenting was performed in two patients due to tumor progression (n=1) and stent fracture (n=1). Removal of a Y-shaped stent was attempted in one patient, but failed, as the stent had become partly embedded in the airway mucosa. In conclusion, cone-shaped Micro-Tech stent placement maintained tracheal-unilateral main bronchus patency and benefitted patients with malignant carinal stenosis in whom Y-shaped stents were not suitable for insertion.

Primary Clinical Application of Y-Shaped Jogged Stent Implantation in Patients with Malignant Hilar Biliary Obstruction

OBJECTIVE

To assess the feasibility, safety, and efficacy of Y-shaped jogged stent in patients with malignant hilar biliary obstruction.

METHODS

A total of 196 patients with malignant hilar biliary obstruction treated by biliary tract stent implantation from August 2010 to August 2017 were retrospectively reviewed. Seventeen consecutive patients who were treated with Y-shaped jogged stent implantation were identified as the Y-shaped jogged stent implantation group. Seventeen matched patients undergoing unilateral stent placement combined with percutaneous transhepatic cholangial drainage (PTCD) were enrolled as the control group. Baseline characteristics of patients, stent patency time, and survival time were compared.

RESULTS

There was no significant difference in the age, gender, tumor type and stage, biliary obstruction classification, bilirubin level at diagnosis, presence of metastasis, or chemotherapy between the Y-stent group and the control group (P > 0.05). One week after surgery, the reduction rate of bilirubin was significantly higher in the Y-stent group (88.2% vs 53.0%, P < 0.05). The mean stent patency time was longer in the Y-stent group (7.3 ± 1.0 months vs 5.7 ± 0.9 months, P < 0.05). The mean survival time of the Y-stent group (9.1 ± 1.5 months) was longer than the control group (7.2 ± 1.1 months, P > 0.05). There was no severe complication occurred in both two groups.

CONCLUSION

Y-shaped jogged stent implantation was a safe, feasible, and effective approach in the treatment of patients with malignant hilar biliary obstruction, with the significantly prolonged stent patency time and survival time.

Combined airway and esophageal stents implantation for malignant tracheobronchial and esophageal disease: A STROBE-compliant article

We aimed to evaluate the safety and efficacy of combined airway and esophageal stents under fluoroscopy guidance and local anesthesia for patients with malignant tracheobronchial and esophageal disease. This retrospective analysis included 35 consecutive patients underwent combined stenting from March 2012 to August 2016. All patients underwent chest computed tomography scans before stenting and during follow-up. Thirty-nine airway stents and 43 esophageal covered stents were implanted. The indication of stenting, technical success and postinterventional complications were collected and analyzed. Thirty-nine airway stents and 43 esophageal covered stents were implanted. Stenting failed in 1 airway stent, and 2 esophageal stents, with technology success rates of 97.4% and 95.3%, respectively. No procedure-related death occurred, only 1 patient died from failure of respiration due to esophagotracheal fistula. The median interval between 2 stenting was 13.0 days. Both dyspnea and dysphasia were significantly relieved after stenting. Restenosis after stenting (7.7%) was the most common complication for airway stenting, all these cases required second stenting. Stent migration (7.0%) was the most common complication after esophageal stenting, 1 case had to receive airway stenting and 1 case received replacement of esophageal stent. During follow up, 23 patients were clinically cured, 2 patients were improved in symptoms, and 1 was invalid. Eight deaths were found in total. The 1-year, 3-year, and 5-year survival rates were 82.4%, 78.8%, and 78.8%, respectively. In conclusion, combined airway and esophageal stents implantation under fluoroscopy guidance and local anesthesia are safe and effective for malignant tracheobronchial and esophageal disease.

Transcatheter arterial chemical infusion for advanced non-small-cell lung cancer: long-term outcome and predictor of survival

PURPOSE

To evaluate the long-term outcome and the predictor of survival in patients treated with transcatheter arterial chemical infusion for advanced non-small-cell lung cancer (NSCLC).

MATERIALS AND METHODS

From May 2008 to August 2014, a total of 40 consecutive patients with advanced NSCLC who underwent transcatheter arterial chemical infusion were enrolled in this retrospective study. Data on patients' characteristics, treatment response and follow-up were collected and analyzed.

RESULTS

A total of 142 cycles of transcatheter arterial chemical infusion were administered to the 40 patients (3.55 cycles per case). In 21 patients, only the bronchial artery was the tumor feeding artery, while in the remaining 19 patients, other arteries in addition to the bronchial artery served as the tumor feeding arteries. Five patients underwent bronchial arterial embolization after transcatheter arterial chemical infusion. There was no serious procedure-related complication. During 1-60 months (mean 11.5 ± 10.0 months) follow-up, 33 patients died. The objective response and disease control rates were 32.5 and 92.5 %, respectively. The mean time to tumor progression and overall survival was 9.2 ± 1.4 and 13.1 ± 2.0 months, respectively. Based on univariate and multivariate analyses, the independent predictors of decreasing overall survival were airway, esophagus, or superior vena cava involvement (P = 0.037) and more tumor feeding arteries in addition to the bronchial artery (P = 0.003).

CONCLUSION

Transcatheter arterial chemical infusion is an easy and effective method for treating patients with advanced NSCLC and it can provide a favorable long-term outcome.